The structure of interleukin-23 reveals the molecular basis of p40 subunit sharing with interleukin-12

被引:105
|
作者
Lupardus, Patrick J.
Garcia, K. Christopher [1 ]
机构
[1] Stanford Univ, Howard Hughes Med Inst, Sch Med, Dept Mol & Cellular Physiol, Stanford, CA 94305 USA
基金
美国国家卫生研究院;
关键词
IL-23; IL-12; cytokine; receptor; crystallography;
D O I
10.1016/j.jmb.2008.07.051
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Interleukin (IL)-23 is a recently identified member of the IL-12 family of heterodimeric cytokines that modulate subpopulations of T helper cells, and both IL-12 and IL-23 are attractive targets for therapy of autoimmune diseases. IL-23 is a binary complex of a four-helix bundle cytokine (p19) and a soluble class I cytokine receptor p40. IL-12 and IL-23 share p40 as an alpha-receptor subunit, yet show only 15% sequence homology between their four-helix cytokines p19 and p35, respectively, and signal through different combinations of shared receptors. In order to elucidate the structural basis of p40 sharing, we have determined a 2.3-angstrom crystal structure of IL-23 for comparison to the previously determined structure of IL-12. The docking mode of p19 to p40 is altered compared to p35, deviating by a tilt and roll that results in an altered footprint of p40 on the A and D helices of the respective cytokines. Binding of p19 to p40 is mediated primarily by an arginine residue on helix D of p19 that forms an extensive charge and hydrogen-bonding network with residues at the base of a pocket on p40. This 'arginine pocket' is lined with an inner shell of hydrophobic interactions that are ringed by an outer shell of polar interactions. Comparative analysis indicates that the IL-23 and IL-12 complexes 'mimic' the network of interactions constituting the central arginine pocket despite p19 and p35 having limited sequence homology. The majority of the structural epitopes in the two complexes are composed of unique p19 and p35 pairwise contacts with common residues on p40. Thus, while the critical hotspot is maintained in the two complexes, the majority of the interfaces are structurally distinct and, therefore, provide a basis for the therapeutic targeting of IL-12 versus IL-23 heterodimer formation despite their use of a common receptor subunit. (C) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码:931 / 941
页数:11
相关论文
共 50 条
  • [31] Increased circulating interleukin-12 (IL-12) p40 in pulmonary sarcoidosis
    Shigehara, K
    Shijubo, N
    Ohmichi, M
    Kamiguchi, K
    Takahashi, R
    Morita-Ichimura, S
    Ohchi, T
    Tatsuno, T
    Hiraga, Y
    Abe, S
    Sato, N
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2003, 132 (01): : 152 - 157
  • [32] Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis
    Koutruba, Nora
    Emer, Jason
    Lebwohl, Mark
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2010, 6 : 123 - 141
  • [33] Interleukin-12 P40 induces the expression of TNF-α in microglia and macrophages
    Jana, M
    Dasgupta, S
    Liu, X
    Pahan, K
    JOURNAL OF NEUROCHEMISTRY, 2002, 81 : 52 - 52
  • [34] Investigation of interleukin-12, interleukin-17 and interleukin-23 receptor gene polymorphisms in alopecia areata
    Aytekin, Nesrin
    Akcali, Cenk
    Pehlivan, Sacide
    Kirtak, Necmettin
    Inaloz, Serhat
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2015, 43 (04) : 526 - 534
  • [35] The localisation of the heparin binding sites of human and murine interleukin-12 within the carboxyterminal domain of the P40 subunit
    Garnier, Pascale
    Mummery, Rosemary
    Forster, Mark J.
    Mulloy, Barbara
    Gibbs, Roslyn V.
    Rider, Christopher C.
    CYTOKINE, 2018, 110 : 159 - 168
  • [36] Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain
    Daniel J. Cua
    Jonathan Sherlock
    Yi Chen
    Craig A. Murphy
    Barbara Joyce
    Brian Seymour
    Linda Lucian
    Wayne To
    Sylvia Kwan
    Tatyana Churakova
    Sandra Zurawski
    Maria Wiekowski
    Sergio A. Lira
    Daniel Gorman
    Robert A. Kastelein
    Jonathon D. Sedgwick
    Nature, 2003, 421 : 744 - 748
  • [37] Interleukin-12, interleukin-23, and psoriasis: ABT-874 in clinical trials - Reply
    Feldman, Steven R.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2008, 58 (06) : 1083 - 1083
  • [38] Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain
    Cua, DJ
    Sherlock, J
    Chen, Y
    Murphy, CA
    Joyce, B
    Seymour, B
    Lucian, L
    To, W
    Kwan, S
    Churakova, T
    Zurawski, S
    Wiekowski, M
    Lira, SA
    Gorman, D
    Kastelein, RA
    Sedgwick, JD
    NATURE, 2003, 421 (6924) : 744 - 748
  • [39] Inhibition of interleukin-12 and/or interleukin-23 for the treatment of psoriasis: What is the evidence for an effect on malignancy?
    Ergen, Elizabeth N.
    Yusuf, Nabiha
    EXPERIMENTAL DERMATOLOGY, 2018, 27 (07) : 737 - 747
  • [40] Dendritic cells resist to disulfiram-induced cytotoxicity, but reduced interleukin-12/23(p40) production
    Jung, Haebeen
    Joo, Hong-Gu
    KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY, 2023, 27 (05): : 471 - 479